← All trials
NCT04342156
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2020
- Primary completion
- Aug 31, 2020
- Completion date
- Oct 31, 2020
- First posted
- Apr 10, 2020
- Last posted
- Apr 20, 2020
- Enrollment
- 1200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nanyang Technological UniversityLead sponsor
- Nanyang Technological UniversityOverall official - principal investigator
- Singapore Eye Research InstituteCollaborator
- Singapore Clinical Research InstituteCollaborator
- Saw Swee Hock School of Public HealthCollaborator
- Government of NetherlandsCollaborator
- National Center for Infectious DiseasesCollaborator
- Duke UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.